Caitlin John’s Oramed Pharmaceuticals ORMP Stock Holding History

Caitlin John’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,000	Closed	-$2.85K	–	984
2025 Q4	$2.85K	Buy	+1,000	New	+$2.58K	﹤0.01%	692

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Caitlin John's ORMP Position: Q1 2026 in Review

Caitlin John sold out of Oramed Pharmaceuticals (ORMP) in Q1 2026, closing a stake of 1,000 shares — an estimated $2.85K sold.

Caitlin John first reported a position in ORMP in Q4 2025 and held it in 1 quarter. The position peaked at $2.85K in Q4 2025. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

Caitlin John reported no remaining Oramed Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Caitlin John sold 1,000 Oramed Pharmaceuticals shares in Q1 2026, an estimated $2.85K.
Caitlin John first reported a position in Oramed Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Caitlin John's Oramed Pharmaceuticals position peaked at $2.85K in Q4 2025.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.